Video

Dr. Contreras on Neoadjuvant Therapies in Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.

Carlo Contreras, MD, surgical oncologist, The Ohio State University Comprehensive Cancer Center (OSUCCC)–James, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC).

Although unmet needs in BCC and CSCC lie in head-to-head, randomized clinical trials with hedgehog inhibitors, it is unlikely that that this will be explored in the future, Contreras explains. However, researchers are attempting to replicate promising results from earlier trials in new, larger trials for patients with CSCC and BCC.

Data on the use of neoadjuvant BRAF-directed therapy in melanoma demonstrate high pathologic complete response rates (pCRs), but also increased risk for short-term recurrence 2 years post-surgical resection, Contreras explains. Accordingly, evaluating long-term data from neoadjuvant trials in CSCC and BCC may reveal the risk of recurrence in this disease setting.

Overall, it is hoped that future research will result in more durable responses than what has been previously seen, he concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity